Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Novartis Announces China Launch for Lucentis and Galvus

publication date: Jan 18, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Novartis received SFDA approval to sell Lucentis (ranibizumab) in China. Lucentis is a treatment for wet (neovascular) age-related macular degeneration (AMD), which causes blindness and vision loss, usually in people over 50. The company also announced the China launch of Galvus (vildagliptin), an oral diabetes treatment. Galvus is a dipeptidyl peptidase IV (DPP-IV) inhibitor indicated for people with diabetes 2. More details....

Stock Symbol: (NYSE: NVS)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...



ChinaBio® Events
Shanghai, China
April 15-16, 2015

>> More events...

Partner Events

China Healthcare Investment Conference
March 31 – April 2, 2015
Shanghai, China

Asia Biotech Invest 2015
May19-21, 2015
Hong Kong, China
>> More events...
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors